Stage IIIA Intraocular Melanoma Recruiting Phase 2 Trials for Sunitinib (DB01268)

IndicationStatusPhase
DBCOND0030838 (Stage IIIA Intraocular Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02068586Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal MelanomaTreatment